N-BUTYRYL SCOPOLAMINE

First marketed in 1899

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H27NO5
Molecular Weight	373.4428
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCC(=O)OC[C@@H](C(=O)O[C@H]1C[C@H]2[C@@H]3O[C@@H]3[C@@H](C1)N2C)C4=CC=CC=C4

InChI

InChIKey=XYACSNDCQGUNGZ-OXAWTZHMSA-N

InChI=1S/C21H27NO5/c1-3-7-18(23)25-12-15(13-8-5-4-6-9-13)21(24)26-14-10-16-19-20(27-19)17(11-14)22(16)2/h4-6,8-9,14-17,19-20H,3,7,10-12H2,1-2H3/t14-,15-,16-,17+,19-,20+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C21H27NO5
Molecular Weight	373.4428
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16175141 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017874s038lbl.pdf

The alkaloid L-(-)-scopolamine [L-(-)-hyoscine], a belladonna alkaloid, competitively inhibits muscarinic receptors for acetylcholine and acts as a nonselective muscarinic antagonist, producing both peripheral antimuscarinic properties and central sedative, antiemetic, and amnestic effects. Scopolamine acts: i) as a competitive inhibitor at postganglionic muscarinic receptor sites of the parasympathetic nervous system, and ii) on smooth muscles that respond to acetylcholine but lack cholinergic innervation. It has been suggested that scopolamine acts in the central nervous system (CNS) by blocking cholinergic transmission from the vestibular nuclei to higher centers in the CNS and from the reticular formation to the vomiting center. Scopolamine can inhibit the secretion of saliva and sweat, decrease gastrointestinal secretions and motility, cause drowsiness, dilate the pupils, increase heart rate, and depress motor function. Scopolamine is used for premedication in anesthesia and for the prevention of nausea and vomiting (post operative and associated with motion sickness).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 3 (5-HT3) receptor 59 Target ID: CHEMBL2094132 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27108935	Antagonist 2849		2.09 µM [IC50]
Muscarinic acetylcholine receptor 162 Target ID: CHEMBL2094109 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1727135 \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017874s038lbl.pdf	Antagonist 2849

Conditions

Condition	Modality	Highest Phase	Product
Motion sickness 43 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017874s038lbl.pdf	Preventing	Approved 8583	TRANSDERM SCOP Approved Use Transderm Scōp is an anticholinergic agent indicated in adults for the prevention of nausea and vomiting associated with: Motion Sickness and Post Operative Nausea and Vomiting (PONV) Launch Date 1979
Postoperative nausea and vomiting 31 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017874s038lbl.pdf	Preventing	Approved 8583	TRANSDERM SCOP Approved Use Transderm Scōp is an anticholinergic agent indicated in adults for the prevention of nausea and vomiting associated with: Motion Sickness and Post Operative Nausea and Vomiting (PONV) Launch Date 1979
Depression 240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17015814 https://www.ncbi.nlm.nih.gov/pubmed/23334071	Primary	Phase IV 63	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
5 ng/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/16175141/	0.5 mg single, intravenous dose: 0.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:		SCOPOLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
369 ng × min/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/16175141/	0.5 mg single, intravenous dose: 0.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:		SCOPOLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.1 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf	1 mg single, topical dose: 1 mg route of administration: Topical experiment type: SINGLE co-administered:		SCOPOLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
68.7 min REVIEW https://pubmed.ncbi.nlm.nih.gov/16175141/	0.5 mg single, intravenous dose: 0.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:		SCOPOLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf	1 mg single, topical dose: 1 mg route of administration: Topical experiment type: SINGLE co-administered:		SCOPOLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
70% REVIEW https://pubmed.ncbi.nlm.nih.gov/16175141/	0.5 mg single, intravenous dose: 0.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:		SCOPOLAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.4 mg single, intranasal Highest studied dose Dose: 0.4 mg Route: intranasal Route: single Dose: 0.4 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/	healthy, 21 - 47 years Health Status: healthy Age Group: 21 - 47 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/	Other AEs: Dizziness, Lightheadedness... Other AEs: Dizziness (3 patients) Lightheadedness (3 patients) Nasal burning (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/
0.9 mg 2 times / day multiple, oral Highest studied dose Dose: 0.9 mg, 2 times / day Route: oral Route: multiple Dose: 0.9 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6873137	healthy, 21.4 years Health Status: healthy Age Group: 21.4 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/6873137	Other AEs: Blurred vision, Dizziness... Other AEs: Blurred vision Dizziness Sources: https://pubmed.ncbi.nlm.nih.gov/6873137
6 ug/kg single, intravenous Dose: 6 ug/kg Route: intravenous Route: single Dose: 6 ug/kg Sources: https://pubmed.ncbi.nlm.nih.gov/6873137	healthy, 22.8 years Health Status: healthy Age Group: 22.8 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/6873137	Sources: https://pubmed.ncbi.nlm.nih.gov/6873137
1.2 mg single, oral Highest studied dose Dose: 1.2 mg Route: oral Route: single Dose: 1.2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3088662	healthy, 24 years (range: 19-38 years) Health Status: healthy Age Group: 24 years (range: 19-38 years) Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/3088662	Other AEs: Dizziness, Dry mouth... Other AEs: Dizziness (4 patients) Dry mouth (3 patients) Blurred vision (4 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/3088662
10 mg 3 times / day multiple, oral Overdose Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25395072	unhealthy, 83 years Health Status: unhealthy Age Group: 83 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/25395072	Other AEs: Consciousness abnormal, Hyperthermia... Other AEs: Consciousness abnormal (1 patient) Hyperthermia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/25395072
0.5 mg single, intravenous Dose: 0.5 mg Route: intravenous Route: single Dose: 0.5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15792397	healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/15792397	Sources: https://pubmed.ncbi.nlm.nih.gov/15792397

AEs

AE	Significance	Dose	Population
Nasal burning	1 patient	0.4 mg single, intranasal Highest studied dose Dose: 0.4 mg Route: intranasal Route: single Dose: 0.4 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/	healthy, 21 - 47 years Health Status: healthy Age Group: 21 - 47 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/
Dizziness	3 patients	0.4 mg single, intranasal Highest studied dose Dose: 0.4 mg Route: intranasal Route: single Dose: 0.4 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/	healthy, 21 - 47 years Health Status: healthy Age Group: 21 - 47 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/
Lightheadedness	3 patients	0.4 mg single, intranasal Highest studied dose Dose: 0.4 mg Route: intranasal Route: single Dose: 0.4 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/	healthy, 21 - 47 years Health Status: healthy Age Group: 21 - 47 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25187210/
Blurred vision		0.9 mg 2 times / day multiple, oral Highest studied dose Dose: 0.9 mg, 2 times / day Route: oral Route: multiple Dose: 0.9 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6873137	healthy, 21.4 years Health Status: healthy Age Group: 21.4 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/6873137
Dizziness		0.9 mg 2 times / day multiple, oral Highest studied dose Dose: 0.9 mg, 2 times / day Route: oral Route: multiple Dose: 0.9 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6873137	healthy, 21.4 years Health Status: healthy Age Group: 21.4 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/6873137
Dry mouth	3 patients	1.2 mg single, oral Highest studied dose Dose: 1.2 mg Route: oral Route: single Dose: 1.2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3088662	healthy, 24 years (range: 19-38 years) Health Status: healthy Age Group: 24 years (range: 19-38 years) Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/3088662
Blurred vision	4 patients	1.2 mg single, oral Highest studied dose Dose: 1.2 mg Route: oral Route: single Dose: 1.2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3088662	healthy, 24 years (range: 19-38 years) Health Status: healthy Age Group: 24 years (range: 19-38 years) Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/3088662
Dizziness	4 patients	1.2 mg single, oral Highest studied dose Dose: 1.2 mg Route: oral Route: single Dose: 1.2 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3088662	healthy, 24 years (range: 19-38 years) Health Status: healthy Age Group: 24 years (range: 19-38 years) Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/3088662
Consciousness abnormal	1 patient	10 mg 3 times / day multiple, oral Overdose Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25395072	unhealthy, 83 years Health Status: unhealthy Age Group: 83 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/25395072
Hyperthermia	1 patient	10 mg 3 times / day multiple, oral Overdose Dose: 10 mg, 3 times / day Route: oral Route: multiple Dose: 10 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25395072	unhealthy, 83 years Health Status: unhealthy Age Group: 83 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/25395072

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087 inhibitor 2252	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2C8 1057 CYP2C19 2057 OCT1 620 OCT2 779 OCT3 159 MATE1 415 MATE2 267	CYP3A 220	CYP1A2 832

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017874s043s044lbl.pdf#page=5 Page: 5.0	no
MATE1 416	inhibitor 4027 Sources: https://www.degruyter.com/document/doi/10.1515/hsz-2016-0236/html Page: 21.0	yes [IC50 119.2 uM]
OCT3 161	inhibitor 4027 Sources: https://www.degruyter.com/document/doi/10.1515/hsz-2016-0236/html Page: 21.0	yes [IC50 217.9 uM]
OCT2 782	inhibitor 4027 Sources: https://www.degruyter.com/document/doi/10.1515/hsz-2016-0236/html Page: 21.0	yes [IC50 540.8 uM]
OCT1 656	inhibitor 4027 Sources: https://www.degruyter.com/document/doi/10.1515/hsz-2016-0236/html Page: 21.0	yes [IC50 6.7 uM]
MATE2 267	inhibitor 4027 Sources: https://www.degruyter.com/document/doi/10.1515/hsz-2016-0236/html Page: 21.0	yes [IC50 699.9 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A 220	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16175141/	yes		yes (co-administration study) Comment: The AUC0–24h values of scopolamine were higher during the grapefruit juice period. They reached approximately 142% of the values associated with the control group (water period; P . 0.005) Sources: https://pubmed.ncbi.nlm.nih.gov/16175141/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:16794	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16794
MolPort	MolPort-005-938-576	https://www.molport.com/shop/molecule-link/MolPort-005-938-576
ZINC	ZINC000100037020	http://zinc15.docking.org/substances/ZINC000100037020

PubMed

Title	Date	PubMed
Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs.	1976 Aug	10058
Effects of physostigmine, scopolamine, and mecamylamine on the sleeping time induced by ketamine in the rat.	1979 Mar 14	108720
Behavioral studies of the effects of moderate oligemic hypoxia caused by bilateral clamping of carotid arteries in mice. Impairment of spatial working memory.	1998 Jul-Oct	10091712
Korean red ginseng saponins with low ratios of protopanaxadiol and protopanaxatriol saponin improve scopolamine-induced learning disability and spatial working memory in mice.	1999 Aug	10433468
Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice.	1999 Jun	10401555
Scopolamine-induced convulsions in food given fasted mice: effects of clonidine and tizanidine.	1999 Jun	10372568
American ginseng extract reduces scopolamine-induced amnesia in a spatial learning task.	1999 Nov	10586535
S 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine.	1999 Nov	10578133
The ameliorating effects of the cognitive-enhancing Chinese herbs on scopolamine-induced amnesia in rats.	2000 Aug	10925408
Serial position effect and selective amnesia induced by scopolamine in mice.	2000 Feb	10890019
Dehydroevodiamine.HCl prevents impairment of learning and memory and neuronal loss in rat models of cognitive disturbance.	2000 Jan	10617126
Intra-medial prefrontal cortex injections of scopolamine increase instrumental responses for cocaine: an intravenous self-administration study in rats.	2000 Jan 15	10709961
Antiamnesic effect of metoprine and of selective histamine H(1) receptor agonists in a modified mouse passive avoidance test.	2000 Jul 7	10869801
Probing peripheral and central cholinergic system responses.	2000 Sep	11022397
Muscarinic cholinergic and glutamatergic reciprocal regulation of expression of hippocampal cholinergic neurostimulating peptide precursor protein gene in rat hippocampus.	2001	11166120
Effects of MDL 73005 on water-maze performances and locomotor activity in scopolamine-treated rats.	2001 Apr	11526961
Decreased scopolamine yield in field-grown Duboisia plants regenerated from hairy roots.	2001 Apr	11345697
The anti-amnesic effects of sigma1 (sigma1) receptor agonists confirmed by in vivo antisense strategy in the mouse.	2001 Apr 13	11292454
Pentyl-4-yn-valproic acid enhances both spatial and avoidance learning, and attenuates age-related NCAM-mediated neuroplastic decline within the rat medial temporal lobe.	2001 Aug	11520891
Ultrasonic vocalizations as an index of social memory in female mice.	2001 Aug	11508722
Inhaled anticholinergic therapy: applied pharmacology and interesting developments.	2001 Jan	11527013
Enterostatin (VPDPR) has anti-analgesic and anti-amnesic activities.	2001 Jan	11272841
[Frey syndrome].	2001 Jan	11272385
Sexual diergism in rat hypothalamic-pituitary-adrenal axis responses to cholinergic stimulation and antagonism.	2001 Jan 1	11226719
Effects of the 5-HT(6) receptor antagonist Ro 04-6790 on learning consolidation.	2001 Jan 8	11163639
Developmental exposure to methylmercury alters behavioral sensitivity to D-amphetamine and pentobarbital in adult rats.	2001 Jan-Feb	11274875
The effects of scopolamine on the spatial organization of cortical potentials in the rat brain.	2001 Jan-Feb	11265815
Effects of Hypericum perforatum (St. John's wort) on passive avoidance in the rat: evaluation of potential neurochemical mechanisms underlying its antidepressant activity.	2001 Jul	11518084
The alpha 2 adrenoceptor antagonists RX 821002 and yohimbine delay-dependently impair choice accuracy in a delayed non-matching-to-position task in rats.	2001 Jun	11441427
Morphological and functional in vitro and in vivo characterization of the mouse corpus cavernosum.	2001 Mar	11250885
Scopolamine reduces the P35m and P60m deflections of the human somatosensory evoked magnetic fields.	2001 Mar 5	11234776
Memory impairment induced by cholinergic antagonists injected into the mushroom bodies of the honeybee.	2001 May	11467497
Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel mucarinic antagonist with M(2)-sparing antagonistic activity.	2001 May	11303071
Intrahippocampal scopolamine impairs both acquisition and consolidation of contextual fear conditioning.	2001 May	11300731
The role of nitric oxide on the relaxations of rabbit corpus cavernosum induced by Androctonus australis and Buthotus judaicus scorpion venoms.	2001 May	11072041
Excitatory nicotinic and desensitizing muscarinic (M2) effects on C-nociceptors in isolated rat skin.	2001 May 1	11312314
Release of non-neuronal acetylcholine from the human placenta: difference to neuronal acetylcholine.	2001 Sep	11521162

Patents

Sample Use Guides

In Vivo Use Guide

Transderm Scōp (scopolamine) transdermal system patch. Each Transderm Scōp patch is formulated to deliver in-vivo approximately 1 mg of scopolamine over 3 days. Initiation of Therapy Motion Sickness To prevent the nausea and vomiting associated with motion sickness, one Transderm Scōp patch (formulated to deliver approximately 1 mg of scopolamine over 3 days) should be applied to the hairless area behind one ear at least 4 hours before the antiemetic effect is required. Post Operative Nausea and Vomiting To prevent post operative nausea and vomiting, one Transderm Scōp patch should be applied the evening before scheduled surgery, except for caesarian section. For caesarian section surgery, to minimize exposure of the newborn baby to the drug, apply the patch one hour prior to caesarian section. Continuation of Therapy Should the patch become displaced, it should be discarded, and a fresh one placed on the hairless area behind the other ear. Motion Sickness If therapy is required for longer than 3 days, the first patch should be removed and a fresh one placed on the hairless area behind the other ear. Post Operative Nausea and Vomiting For perioperative use, the patch should be kept in place for 24 hours following surgery at which time it should be removed and discarded.

Route of Administration: Transdermal

In Vitro Use Guide

Rosmarinic acid treatment increases the expression of BDNF and GluR-2 proteins and prevents cell death of scopolamine-exposed (300 μM) organotypic hippocampal slice cultures.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 20:50:49 GMT 2025` Edited by `admin` on `Mon Mar 31 20:50:49 GMT 2025`
Record UNII	HO322TV6PV
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

N-BUTYRYL SCOPOLAMINE

Common Name

English

BENZENEACETIC ACID, .ALPHA.-((1-OXOBUTOXY)METHYL)-, 9-METHYL-3-OXA-9-AZATRICYCLO(3.3.1.0(SUP 2,4))NON-7-YL ESTER, (7(S)-(1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.))-

Preferred Name

English

N-BUTYRYLSCOPOLAMINE

Common Name

English

Code System Code Type Description

FDA UNII

HO322TV6PV

Created by admin on Mon Mar 31 20:50:49 GMT 2025 , Edited by admin on Mon Mar 31 20:50:49 GMT 2025

PRIMARY

CAS

740757-65-7

Created by admin on Mon Mar 31 20:50:49 GMT 2025 , Edited by admin on Mon Mar 31 20:50:49 GMT 2025

PRIMARY

PUBCHEM

71587791

Created by admin on Mon Mar 31 20:50:49 GMT 2025 , Edited by admin on Mon Mar 31 20:50:49 GMT 2025

PRIMARY

Related Record Type Details


					DL48G20X8X

SCOPOLAMINE

METABOLITE ACTIVE -> PRODRUG

Related Record Type Details


					DL48G20X8X

SCOPOLAMINE

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16175141 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017874s038lbl.pdf

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16175141 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017874s038lbl.pdf

C_max

T_1/2

F_unbound

Drug as perpetrator